Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
June 07, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Paulson Investment Company
Deal Size : $4.0 million
Deal Type : Public Offering
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
Details : The net proceeds are expected to support advancement of Akari’s two priority pipeline programs investigating rVA576 (nomacopan), a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4).
Product Name : Coversin
Product Type : Protein
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Paulson Investment Company
Deal Size : $4.0 million
Deal Type : Public Offering
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manu
Details : rVA576 (nomacopan) is a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) in clinical development for pediatric and adult HSCT-TMA.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
March 04, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rVA576 (nomacopan) is a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) in clinical development for pediatric and adult HSCT-TMA.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Alliance Global Partners
Deal Size : $12.7 million
Deal Type : Public Offering
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
Details : Net proceeds from the transaction are expected to support advancement of Akari’s two priority pipeline programs investigating nomacopan (rVA576), a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4).
Product Name : Coversin
Product Type : Protein
Upfront Cash : Undisclosed
December 09, 2022
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Alliance Global Partners
Deal Size : $12.7 million
Deal Type : Public Offering
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nomacopan (rVA576), is a recombinant small protein derived from a protein originally discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rVA576 (nomacopan), is a bispecific recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy .
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable